Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, Phase 2 study to evaluate efficacy and safety of PD1
inhibitor Camrelizumab(SHR-1210) combined with Gemox in patients with relapsed and refractory
hodgkin lymphoma who will receive ASCT.Efficacy will be assessed according to 2014 Lugano
criteria.